Starr Cancer Consortium RFA

Through a generous gift from the Starr Foundation, five institutions in New York and Boston have formed the Starr Cancer Consortium, a collaborative framework to advance research in new ways that will have an impact on the understanding, diagnosis, prevention or treatment of cancer.

The five participating institutions in the Starr Cancer Consortium are the Broad Institute of MIT and Harvard, Cold Spring Harbor Laboratory, Memorial Sloan-Kettering Cancer Center, Rockefeller University, and Weill Medical College of Cornell University.

The Starr Cancer Consortium is intended largely to support critical mass, collaborative projects with the potential for transforming impact on the understanding and treatment of cancer, through the development and systematic application of molecular technologies, by investigating cancer biology or addressing important clinical problems. It is aimed at encouraging meaningful and ambitious collaborations between the participating institutions to develop and apply innovative approaches to transform cancer research and ultimately diagnostic and therapeutic strategies.

All projects supported by the Consortium must be collaborative, involving investigators from two or more of the five participating institutions.

An overview outlining the goals of the Starr Cancer Consortium program can be found here.